Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Biosynthesis of microcystin hepatotoxins in the cyanobacterial genus Fischerella.

Heck K, Alvarenga DO, Shishido TK, Varani AM, Dörr FA, Pinto E, Rouhiainen L, Jokela J, Sivonen K, Fiore MF.

Toxicon. 2018 Jan;141:43-50. doi: 10.1016/j.toxicon.2017.10.021. Epub 2017 Nov 27.

PMID:
29154789
2.

Identification of hispidin as a bioluminescent active compound and its recycling biosynthesis in the luminous fungal fruiting body.

Oba Y, Suzuki Y, Martins GNR, Carvalho RP, Pereira TA, Waldenmaier HE, Kanie S, Naito M, Oliveira AG, Dörr FA, Pinto E, Yampolsky IV, Stevani CV.

Photochem Photobiol Sci. 2017 Sep 13;16(9):1435-1440. doi: 10.1039/c7pp00216e.

PMID:
28766678
3.
4.

Mechanism and color modulation of fungal bioluminescence.

Kaskova ZM, Dörr FA, Petushkov VN, Purtov KV, Tsarkova AS, Rodionova NS, Mineev KS, Guglya EB, Kotlobay A, Baleeva NS, Baranov MS, Arseniev AS, Gitelson JI, Lukyanov S, Suzuki Y, Kanie S, Pinto E, Di Mascio P, Waldenmaier HE, Pereira TA, Carvalho RP, Oliveira AG, Oba Y, Bastos EL, Stevani CV, Yampolsky IV.

Sci Adv. 2017 Apr 26;3(4):e1602847. doi: 10.1126/sciadv.1602847. eCollection 2017 Apr.

5.

Genetic Organization of Anabaenopeptin and Spumigin Biosynthetic Gene Clusters in the Cyanobacterium Sphaerospermopsis torques-reginae ITEP-024.

Lima ST, Alvarenga DO, Etchegaray A, Fewer DP, Jokela J, Varani AM, Sanz M, Dörr FA, Pinto E, Sivonen K, Fiore MF.

ACS Chem Biol. 2017 Mar 17;12(3):769-778. doi: 10.1021/acschembio.6b00948. Epub 2017 Jan 26.

PMID:
28085246
6.

Polyphenols from Chilean Propolis and Pinocembrin Reduce MMP-9 Gene Expression and Activity in Activated Macrophages.

Saavedra N, Cuevas A, Cavalcante MF, Dörr FA, Saavedra K, Zambrano T, Abdalla DS, Salazar LA.

Biomed Res Int. 2016;2016:6505383. doi: 10.1155/2016/6505383. Epub 2016 Mar 28.

7.

First report of spumigin production by the toxic Sphaerospermopsis torques-reginae cyanobacterium.

Sanz M, Dörr FA, Pinto E.

Toxicon. 2015 Dec 15;108:15-8. doi: 10.1016/j.toxicon.2015.09.019. Epub 2015 Sep 21.

PMID:
26394197
8.

Can creatine supplementation form carcinogenic heterocyclic amines in humans?

Pereira RT, Dörr FA, Pinto E, Solis MY, Artioli GG, Fernandes AL, Murai IH, Dantas WS, Seguro AC, Santinho MA, Roschel H, Carpentier A, Poortmans JR, Gualano B.

J Physiol. 2015 Sep 1;593(17):3959-71. doi: 10.1113/JP270861. Epub 2015 Jul 30.

10.

Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases.

Gomes MM, Coimbra JB, Clara RO, Dörr FA, Moreno AC, Chagas JR, Tufik S, Pinto E Jr, Catalani LH, Campa A.

Biochem Pharmacol. 2014 Apr 1;88(3):393-401. doi: 10.1016/j.bcp.2014.01.035. Epub 2014 Feb 6.

11.

Cylindrospermopsin and saxitoxin synthetase genes in Cylindrospermopsis raciborskii strains from Brazilian freshwater.

Hoff-Risseti C, Dörr FA, Schaker PD, Pinto E, Werner VR, Fiore MF.

PLoS One. 2013 Aug 28;8(8):e74238. doi: 10.1371/journal.pone.0074238. eCollection 2013.

12.

Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells.

Tourino MC, de Oliveira EM, Bellé LP, Knebel FH, Albuquerque RC, Dörr FA, Okada SS, Migliorini S, Soares IS, Campa A.

Cell Biochem Funct. 2013 Jul;31(5):361-4. doi: 10.1002/cbf.2980. Epub 2013 Jun 10.

PMID:
23754498
13.

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.

Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, Costa AL, Chamone DA, Bendit I.

Rev Bras Hematol Hemoter. 2013;35(2):103-8. doi: 10.5581/1516-8484.20130030.

14.

Co-occurrence of microcystin and microginin congeners in Brazilian strains of Microcystis sp.

Carneiro RL, Dörr FA, Dörr F, Bortoli S, Delherbe N, Vásquez M, Pinto E.

FEMS Microbiol Ecol. 2012 Dec;82(3):692-702. doi: 10.1111/j.1574-6941.2012.01439.x. Epub 2012 Jul 30.

15.

Intriguing differences in the gas-phase dissociation behavior of protonated and deprotonated gonyautoxin epimers.

Dörr FA, Kovačevi B, Maksi ZB, Pinto E, Volmer DA.

J Am Soc Mass Spectrom. 2011 Nov;22(11):2011-20. doi: 10.1007/s13361-011-0223-8. Epub 2011 Aug 16.

PMID:
21952766
16.

Anti-atherogenic and anti-angiogenic activities of polyphenols from propolis.

Daleprane JB, Freitas Vda S, Pacheco A, Rudnicki M, Faine LA, Dörr FA, Ikegaki M, Salazar LA, Ong TP, Abdalla DS.

J Nutr Biochem. 2012 Jun;23(6):557-66. doi: 10.1016/j.jnutbio.2011.02.012. Epub 2011 Jul 20.

PMID:
21764281
17.

Dissociation of deprotonated microcystin variants by collision-induced dissociation following electrospray ionization.

Dörr FA, Oliveira-Silva D, Lopes NP, Iglesias J, Volmer DA, Pinto E.

Rapid Commun Mass Spectrom. 2011 Jul 30;25(14):1981-92. doi: 10.1002/rcm.5083.

PMID:
21698681
18.

Microcystins in South American aquatic ecosystems: Occurrence, toxicity and toxicological assays.

Dörr FA, Pinto E, Soares RM, Feliciano de Oliveira e Azevedo SM.

Toxicon. 2010 Dec 15;56(7):1247-56. doi: 10.1016/j.toxicon.2010.03.018. Epub 2010 Apr 1. Review.

PMID:
20362607
19.

Methods for detection of anatoxin-a(s) by liquid chromatography coupled to electrospray ionization-tandem mass spectrometry.

Dörr FA, Rodríguez V, Molica R, Henriksen P, Krock B, Pinto E.

Toxicon. 2010 Jan;55(1):92-9. doi: 10.1016/j.toxicon.2009.07.017. Epub 2009 Jul 24.

PMID:
19632258
20.

Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage.

Pires AP, De Oliveira CD, Moura S, Dörr FA, Silva WA, Yonamine M.

Phytochem Anal. 2009 Mar-Apr;20(2):149-53. doi: 10.1002/pca.1110.

PMID:
19140116
21.

Comparative analysis of the gas-phase reactions of cylindrospermopsin and the difference in the alkali metal cation mobility.

Dörr FA, Tomaz JC, Lopes NP, Pinto E.

Rapid Commun Mass Spectrom. 2008 Jul;22(13):2015-20. doi: 10.1002/rcm.3567.

PMID:
18512847
22.

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ.

J Hepatol. 2006 Jan;44(1):88-96. Epub 2005 Oct 25.

PMID:
16274834
23.

Perspectives of digestive pest control with proteinase inhibitors that mainly affect the trypsin-like activity of Anticarsia gemmatalis Hübner (Lepidoptera: Noctuidae).

Pereira ME, Dörr FA, Peixoto NC, Lima-Garcia JF, Dörr F, Brito GG.

Braz J Med Biol Res. 2005 Nov;38(11):1633-41. Epub 2005 Oct 26.

24.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.

Invest New Drugs. 2005 Oct;23(5):467-77.

PMID:
16133798
27.

A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

Marshall JL, Eisenberg SG, Johnson MD, Hanfelt J, Dorr FA, El-Ashry D, Oberst M, Fuxman Y, Holmlund J, Malik S.

Clin Colorectal Cancer. 2004 Nov;4(4):268-74.

PMID:
15555210
28.

Clinical studies of antisense oligonucleotides for cancer therapy.

Orr RM, Dorr FA.

Methods Mol Med. 2005;106:85-111. Review. No abstract available.

PMID:
15375314
29.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA.

Clin Cancer Res. 2003 Jan;9(1):115-23.

30.

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.

Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA.

J Pharmacol Exp Ther. 2002 Dec;303(3):1334-43.

31.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

32.
33.

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP.

Br J Cancer. 2001 Nov 30;85(11):1753-8.

34.

Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.

Curr Opin Mol Ther. 1999 Jun;1(3):372-85. Review.

PMID:
11713802
35.

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ.

Clin Cancer Res. 2001 May;7(5):1214-20.

36.

Antisense approaches for the treatment of cancer.

Monia BP, Holmlund J, Dorr FA.

Cancer Invest. 2000;18(7):635-50. Review. No abstract available.

PMID:
11036471
37.

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS.

Clin Cancer Res. 1999 Dec;5(12):3977-82.

38.

Tamoxifen and fenretinide in women with metastatic breast cancer.

Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, Flanders C, Caruso R, Kaiser M, Goodman L, Merino M, Gossard M, Noone MA, Denicoff A, Venzon D, Cowan KH, O'Shaughnessy JA.

Breast Cancer Res Treat. 1999 Oct;57(3):277-83.

PMID:
10617304
39.

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ.

J Clin Oncol. 1999 Jul;17(7):2227-36.

PMID:
10561280
40.

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD.

Cancer Chemother Pharmacol. 1999;44(5):372-80.

PMID:
10501910
41.

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA.

J Clin Oncol. 1997 Nov;15(11):3394-8.

PMID:
9363871
42.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD.

J Clin Oncol. 1997 Jun;15(6):2403-13.

PMID:
9196156
43.

Metastatic bladder cancer: advances in treatment.

Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA.

Eur J Cancer. 1997 Jan;33 Suppl 1:S23-6. Review.

PMID:
9166096
44.

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.

Copley-Merriman C, Corral J, King K, Whiteside R, Voi M, Dorr FA, McDonald RC.

Lung Cancer. 1996 Feb;14(1):45-61.

PMID:
8696720
45.

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, et al.

J Clin Oncol. 1995 Nov;13(11):2842-50.

PMID:
7595747
46.

Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.

Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, Dorr FA, Benson M, Spaulding JT.

Semin Oncol. 1994 Oct;21(5):613-9. No abstract available.

PMID:
7939752
47.

Prognostic factors observed in current clinical trials.

Dorr FA.

Cancer. 1993 Mar 15;71(6 Suppl):2163-8. Review.

PMID:
8443767
48.

Controversies in the treatment of metastatic prostate cancer.

McLeod DG, Crawford ED, Blumenstein BA, Eisenberger MA, Dorr FA.

Cancer. 1992 Jul 1;70(1 Suppl):324-8.

PMID:
1600494
49.

Unanswered questions in the adjuvant therapy of breast cancer.

Dorr FA, Friedman MA.

Cancer Treat Res. 1992;60:257-78. Review. No abstract available.

PMID:
1355990
50.

Potential role of tamoxifen in prevention of breast cancer.

Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS.

J Natl Cancer Inst. 1991 Oct 16;83(20):1450-9. Review.

PMID:
1920492

Supplemental Content

Support Center